Royalty Pharma CFO entities sell 34,791 shares

Royalty Pharma plc reported that entities associated with EVP & CFO Terrance P. Coyne sold Class A Ordinary Shares of the company.

Rhea-AI Filing Summary

Royalty Pharma plc reported that entities associated with EVP & CFO Terrance P. Coyne sold Class A Ordinary Shares of the company. On March 23, 2026, TPC RP 2021, LLC sold 32,916 shares and TPC RP EPA1 LLC sold 1,875 shares in open-market transactions at a weighted average price of $45.5287 per share, with individual prices ranging from $45.30 to $45.94.

All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP 2021, LLC held 65,832 shares and TPC RP EPA1 LLC held 43,886 shares, and Coyne also reported additional indirect and direct holdings through various IRA and family accounts.

Insider Trade Summary 10b5-1

Net Seller: 34,791 shares

Net Sell 6 txns

Insider Coyne Terrance P.

Role EVP & CFO

Sold 34,791 shs ($1.58M)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	32,916	$45.5287	$1.50M
Sale	Class A Ordinary Shares	1,875	$45.5287	$85K
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 65,832 shares (Indirect, By TPC RP 2021, LLC); Class A Ordinary Shares — 43,886 shares (Indirect, TPC RP EPA1 LLC); Class A Ordinary Shares — 24,170 shares (Indirect, By Spouse's IRA); Class A Ordinary Shares — 23,270 shares (Indirect, By IRA); Class A Ordinary Shares — 1,500 shares (Direct); Class A Ordinary Shares — 1,450 shares (Indirect, By Spouse)

Footnotes (2)

1. F1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.30 to $45.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Royalty Pharma (RPRX) report for Terrance P. Coyne?

Royalty Pharma reported that entities associated with EVP & CFO Terrance P. Coyne sold Class A Ordinary Shares. On March 23, 2026, two affiliated LLCs executed open-market sales totaling 34,791 shares of Royalty Pharma at a weighted average price of $45.5287 per share.

Which entities sold Royalty Pharma (RPRX) shares in this Form 4 filing?

The sales were made by TPC RP 2021, LLC and TPC RP EPA1 LLC, entities associated with EVP & CFO Terrance P. Coyne. TPC RP 2021, LLC sold 32,916 shares, while TPC RP EPA1 LLC sold 1,875 shares of Royalty Pharma Class A Ordinary Shares.

At what price were the Royalty Pharma (RPRX) shares sold in the reported transactions?

The filing shows a weighted average sale price of $45.5287 per share. Footnotes explain the shares were sold in multiple transactions, with prices ranging from $45.30 to $45.94 per share across the executed open-market trades reported in this Form 4.

How many Royalty Pharma (RPRX) shares do the LLCs hold after the sales?

After the reported sales, TPC RP 2021, LLC held 65,832 shares of Royalty Pharma Class A Ordinary Shares. TPC RP EPA1 LLC held 43,886 shares. The Form 4 also reports additional indirect and direct holdings through IRA and family accounts linked to Terrance P. Coyne.

Was the Royalty Pharma (RPRX) CFO’s share sale made under a 10b5-1 trading plan?

Yes. A footnote states all reported transactions were effected under a Rule 10b5-1 trading plan adopted by Terrance P. Coyne on August 8, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine diversification from discretionary market-timing decisions.

What role does Terrance P. Coyne hold at Royalty Pharma (RPRX)?

Terrance P. Coyne is identified as EVP & CFO of Royalty Pharma. The Form 4 shows that multiple reported holdings and transactions in Royalty Pharma Class A Ordinary Shares are attributed to entities and accounts associated with him, including LLCs and IRA-related accounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	03/23/2026		S(1)		32,916	D	$45.5287(2)	65,832	I	By TPC RP 2021, LLC
Class A Ordinary Shares	03/23/2026		S(1)		1,875	D	$45.5287(2)	43,886	I	TPC RP EPA1 LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.30 to $45.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,807,277 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)